Aprea Reports Second Partial Response in Phase 1 APR-1051 Trial
DOYLESTOWN, PA — Aprea Therapeutics Inc. (Nasdaq: APRE) reported additional preliminary data from its ongoing Phase 1 ACESOT-1051 trial showing a second unconfirmed partial response in a patient with advanced …
Aprea Reports Second Partial Response in Phase 1 APR-1051 Trial Read More